Zovegalisib
Relay Therapeutics: company profile
Phase 3 registry
Since , the date of the source that reports this phase.
Summary
Zovegalisib is a program from Relay Therapeutics. The source describes it as small molecule. It is being developed for PIK3CA-mutant HR+/HER2- advanced breast cancer. ClinicalTrials.gov lists it at Phase 3 (recruiting) under NCT06982521, NCT06789913, NCT05216432. The AI role named in the source is computational design. Registry records: NCT06982521, Phase 3, recruiting, updated Oct 5, 2026; NCT06789913, Phase 2, recruiting, updated Aug 25, 2026; NCT05216432, Phase 1, recruiting, updated Sep 22, 2025. The latest dated source is from Sep 10, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Relay Therapeutics
- Indication
- PIK3CA-mutant HR+/HER2- advanced breast cancer
- Therapeutic area
- Oncology
- Modality
- Small molecule
- AI role
- Computational design
- Phase in the source
- Phase 3, as of Sep 10, 2026
- Phase source
- Registry
- Board column
- Phase 3
AI evidence
AI source: Paper
Exception: this drug stays on the board although no source ties AI to it specifically. See the inclusion rule.
Discovered with Relay's Dynamo platform, using motion-based computational design (long-timescale molecular dynamics).
Trial records
- NCT06982521 on ClinicalTrials.gov (opens in new tab) Phase 3 Recruiting Updated
- NCT06789913 on ClinicalTrials.gov (opens in new tab) Phase 2 Recruiting Updated
- NCT05216432 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
NCT05216432 record updated
Phase 1, Recruiting
-
NCT06789913 record updated
Phase 2, Recruiting
-
ClinicalTrials.gov record: Phase 3
-
NCT06982521 record updated
Phase 3, Recruiting
Spot an error? Tell me and I'll fix it.